Skip to content

Finished goods at other companies

Eli Lilly logo
Eli LillyLLY
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Exelixis logo
ExelixisEXEL
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$6.64B+77.3%
Enterprise value$6.69B+78.4%
P/S30.6×+3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s finished goods?
Rhythm Pharmaceuticals, Inc. (RYTM) reported finished goods of $21.22M in Q1 2026.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.